Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Not Recruiting

Trial ID: NCT00002756

Purpose

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them as induction intensification may kill more cancer cells. PURPOSE: This phase II trial is studying how well induction intensification works in treating infants with newly diagnosed acute lymphocytic leukemia.

Official Title

Induction Intensification in Infant ALL: A Children's Oncology Group Study

Stanford Investigator(s)

Eligibility

DISEASE CHARACTERISTICS:

* Newly diagnosed acute lymphoblastic leukemia (ALL) or acute undifferentiated leukemia

* No infants less than 36 weeks' gestation
* CNS or testicular disease permitted
* No B-cell ALL or acute myeloid leukemia
* Previously untreated except for the following:

* Steroid treatment within 48 hours of diagnosis allowed with physical examination and differential CBC immediately prior to beginning steroids
* Concurrent registration on protocol POG-9900 (ALL classification study) required
* Patients registered on POG-9407 are eligible for the pharmacokinetic part of the study

PATIENT CHARACTERISTICS:

Age:

* Under 1 at diagnosis

Performance status:

* Not specified

Life expectancy:

* Not specified

Hematopoietic:

* Not specified

Hepatic:

* Not specified

Renal:

* Not specified

Other:

* No uncontrolled infection
* Adequate major organ function

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* Not specified

Endocrine therapy:

* See Disease Characteristics
* No concurrent chronic steroid treatment

Radiotherapy:

* Not specified

Surgery:

* Not specified

Other:

* No other concurrent anticancer therapy

Intervention(s):

biological: filgrastim

drug: asparaginase

drug: cyclophosphamide

drug: cytarabine

drug: daunorubicin hydrochloride

drug: etoposide

drug: leucovorin calcium

drug: mercaptopurine

drug: methotrexate

drug: prednisone

drug: therapeutic hydrocortisone

drug: vincristine sulfate

biological: filgrastim

drug: asparaginase

drug: cyclophosphamide

drug: cytarabine

drug: daunorubicin hydrochloride

drug: etoposide

drug: leucovorin calcium

drug: mercaptopurine

drug: methotrexate

drug: prednisone

drug: therapeutic hydrocortisone

drug: vincristine sulfate

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305